Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
107 hedge funds and large institutions have $125M invested in Accelerate Diagnostics in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 14 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 24
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 105 → 107 (+2)
10% less capital invested
Capital invested by funds: $138M → $125M (-$13.4M)
92% less call options, than puts
Call options by funds: $109K | Put options by funds: $1.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$2.23M |
| 2 |
JP Morgan Chase
New York
|
+$1.9M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$1.88M |
| 4 |
Two Sigma Advisers
New York
|
+$1.73M |
| 5 |
Two Sigma Investments
New York
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
-$3.44M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
-$3.14M |
| 3 |
LA
Linden Advisors
New York
|
-$1.78M |
| 4 |
SM
Selkirk Management
Chatham,
New Jersey
|
-$1.53M |
| 5 |
GAM
Griffin Asset Management
New York
|
-$1.35M |
AXDX Hedge Fund Activity: Q4 2021 in Review
107 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2021, worth a combined $125M — down 9.7% from $138M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AXDX positions and 14 closed out — a net gain of 2 holders — while 45 added to existing stakes and 24 trimmed.
The largest buyer was Baird Financial Group, adding an estimated $2.23M. The largest seller was PenderFund Capital Management, exiting entirely with an estimated $3.44M sold.
- 107 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2021, up from 105 in Q3 2021.
- Funds reported $125M of Accelerate Diagnostics stock for Q4 2021, down 9.7% quarter-over-quarter.
- 16 funds opened new Accelerate Diagnostics positions in Q4 2021 and 14 closed out, a net change of +2 holders.
- The largest Accelerate Diagnostics buyer in Q4 2021 was Baird Financial Group, an estimated $2.23M added.
- The largest Accelerate Diagnostics seller in Q4 2021 was PenderFund Capital Management, an estimated $3.44M sold.
Based on aggregated 13F filings for Q4 2021.